Drug intelligence / Profile preview

Erren Decoction

Development stage: Preclinical
Lead developer: Guangdong Basic and applied basic Research Fund Enterprise joint fund
Administration: Oral

Overview

Erren Decoction is a traditional Chinese herbal formula investigated for its therapeutic effects in treating metrorrhagia and metrostaxis, particularly when associated with the deficiency of spleen and kidney according to Traditional Chinese Medicine principles. It is being studied in clinical trials to evaluate its efficacy and to research its pharmacodynamic substances.

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)RELA (Nuclear Factor Kappa B Subunit p65)NOS2 (Nitric Oxide Synthase 2)ESR1 (ERα)ESR2 (ERβ)

Beyond the preview

Go deeper on Erren Decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Erren Decoction.

Explore the full profile